Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123376) titled 'Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects' on Aug. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Diagnostic. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

Condition: Healthy Volunteers

Intervention: Drug: HRS-9231

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 5, 2024

Target Sample Size: 40

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct...